Biopharmaceutical Processing Equipment and Consumables Market (2026-2036)
The global Biopharmaceutical Processing Equipment and Consumables Market was valued at USD 41.4 billion in 2025. This market is expected to reach USD 108.7 billion by 2036 from an estimated USD 44.8 billion in 2026, registering a CAGR of 9.3% during the forecast period (2026-2036).
- Published
- Sep 2026
- Pages
- 280
- Format
- PDF + Excel
- Report ID
- MR-58
- Base year
- 2025
- 2025 · BASELINE
- $41.40B
- 2036
- $108.7B
- CAGR 2026–2036
- 9.3%
2025 baseline · 2026–2036 forecast at 9.3% CAGR · hover a bar for the value
Key highlights
The global Biopharmaceutical Processing Equipment and Consumables Market was valued at USD 41.4 billion in 2025.
This market is expected to reach USD 108.7 billion by 2036 from an estimated USD 44.8 billion in 2026, registering a CAGR of 9.3% during the forecast period (2026-2036).
In 2026, Europe is expected to account for the largest share of 33.6% of the global Biopharmaceutical Processing Equipment and Consumables Market.
North America is expected to account for the second-largest share of 31.0% of the market in 2026 and to grow at a CAGR of 9.3%, faster than Europe.
However, Asia-Pacific is projected to register the highest CAGR of 10.3% during the forecast period. The growth of this region is driven by CDMO expansion in South Korea, where Samsung Biologics reached 784,000 liters of capacity and 18 biosimilars were approved in 2024, the recovery of domestic biologics and CDMO demand in China, and vaccine and biosimilar production in India.
Latin America is expected to account for a share of 3.3% of the market in 2026. The market is driven by vaccine producers such as Instituto Butantan and Fiocruz in Brazil and growing biosimilar production in Brazil and Mexico, while limited capital budgets favor stainless-steel and lower-cost equipment.
The Middle East & Africa is expected to account for a share of 1.9% of the market in 2026 and to grow at a CAGR of 9.8%, driven by local vaccine and biologics manufacturing initiatives in Saudi Arabia, the United Arab Emirates, Egypt and South Africa.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 9.3% |
| Format | PDF, Excel & Cloud Portal · 280 pages |
| Market Size (Value) in 2026 | USD 44.8 Billion |
| Market Size (Value) in 2036 | USD 108.7 Billion |
| Segments Covered | By Product Type: Filtration Systems; Chromatography Equipment and Consumables (Chromatography Consumables, Chromatography Equipment); Bioreactors (Single-use, Reusable); Cell Culture Products (Cell Culture Media [by Physical Form: Dry Powder, Liquid; by Type: Off-the-Shelf, Custom; by Source: Chemically Defined, Natural], Reagents and Supplements, Cells and Cell Lines, Cell Culture Serum); Bioprocessing Containers; Sterilizers; Mixers/Mixing Systems; Incubators; Centrifuges; Shakers; Biosafety Cabinets; Other Consumables and Accessories; Support Services. By Application: Commercial Bioproduction (Monoclonal Antibody Production, Therapeutic Protein Production, Vaccine Production, Cell and Gene Therapy), Research Bioproduction. By End User: Pharmaceutical & Biopharmaceutical Companies, CDMOs, Academic & Research Institutes. |
| Countries Covered | Europe: Germany, France, U.K., Italy, Spain, Ireland, Denmark, Belgium, Switzerland, Rest of Europe. North America: U.S., Canada. Asia-Pacific: China, India, Japan, South Korea, Rest of Asia-Pacific. Latin America. Middle East & Africa. |
| Key Companies | Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Sartorius AG, Danaher Corporation, Merck KGaA, Avantor, Inc., Bio-Rad Laboratories, Inc., Eppendorf SE, Solaris Biotechnology Srl, and Repligen Corporation. |
Report overview
Segments covered: product type, product, application, end user.
Biopharmaceutical Processing Equipment and Consumables Market Size
The growth of this market is mainly driven by the growing biopharmaceuticals market and the strong pipeline of antibodies, biosimilars and advanced therapies, biopharmaceutical plant capacity expansions, including the onshoring of biologics production to the U.S., and the rising adoption of single-use bioprocessing equipment. In addition, emerging economies, the shift toward Bioprocessing 4.0, and the rising adoption of personalized medicines, such as cell and gene therapies, are expected to create growth opportunities for players operating in this market.
Biopharmaceutical Processing Equipment and Consumables Market Key Highlights
The global Biopharmaceutical Processing Equipment and Consumables Market is projected to reach USD 108.7 billion by 2036, driven by new biologics capacity, U.S. onshoring, CDMO expansion in Asia and the continued shift to single-use technologies.
Europe is expected to account for the largest market share of 33.6% in 2026, while Asia-Pacific is projected to register the fastest growth at a CAGR of 10.3% during the forecast period, and India is projected to register the highest CAGR of any country, at 12.4%.
By product type, the Filtration Systems segment is expected to account for the largest market share of 21.1% in 2026, whereas the Bioreactors segment is projected to register the highest CAGR of 11.0%; within bioreactors, single-use bioreactors are projected to grow at 12.8%.
By application, Commercial Bioproduction is expected to account for 77.6% of the market in 2026, with Monoclonal Antibody Production the largest application and Cell and Gene Therapy the fastest-growing, at a CAGR of 14.3%.
By end user, CDMOs are projected to register the highest CAGR of 11.1%, supported by capacity additions such as Samsung Biologics, which reached 784,000 liters of capacity with its fifth plant.
Bioprocessing demand recovered in 2025 after two years of destocking: Sartorius Bioprocess Solutions sales rose 9.5% in constant currencies to EUR 2,865 million, Merck KGaA Process Solutions sales rose 10.7% organically to EUR 3.8 billion, and Repligen revenue rose 16% to USD 738 million.
The U.S. Section 232 proclamation of April 2, 2026, imposes tariffs of up to 100% on patented pharmaceutical imports from September 29, 2026, for companies without onshoring agreements, after major drugmakers pledged more than USD 370 billion of U.S. investments in 2025.
Consolidation is reshaping supply: Thermo Fisher Scientific completed its USD 4.0 billion acquisition of the Solventum purification and filtration business in September 2025, Merck KGaA agreed to acquire Bio-Techne for about USD 11.3 billion in June 2026, and Repligen agreed to acquire BioLife Solutions in July 2026.
Biopharmaceutical Processing Equipment and Consumables Market Overview
The Biopharmaceutical Processing Equipment and Consumables Market comprises the equipment, consumables and services used to develop and manufacture biologics, including monoclonal antibodies, therapeutic proteins, vaccines and cell and gene therapies. It covers upstream processing (cell culture media, reagents, cell lines and bioreactors), downstream processing (clarification, chromatography and filtration), single-use bioprocessing containers and assemblies, supporting equipment such as mixers, incubators, centrifuges, shakers, sterilizers and biosafety cabinets, and support services such as validation and maintenance.
Bioprocessing is a recurring-revenue market. Once a biologic is approved, its manufacturing process, including the filters, resins, media and single-use components, is specified in the regulatory filing and is rarely changed, so every commercial product creates demand for consumables over its lifetime. Consumables accounted for a large majority of the 2025 bioprocess sales of Sartorius, and filtration and chromatography consumables are the largest product categories.
The market passed through a destocking period in 2023–2024, when customers reduced inventories built up during the COVID-19 pandemic and delayed capital projects. Growth returned in 2025, led by consumables, while equipment sales still declined at several suppliers. In 2026, equipment demand began to recover: Danaher reported mid-teens growth in bioprocessing orders in the second quarter of 2026 and described the industry as being in the early stage of a multi-year capital spending cycle driven by reshoring.
The geography of production is changing. U.S. tariffs on patented pharmaceutical imports from September 2026, together with more than USD 370 billion of U.S. investment pledges, are shifting new capacity toward the U.S., while CDMOs in South Korea, China and India continue to add large-scale capacity. Suppliers are responding with in-region manufacturing; Cytiva has completed USD 1.6 billion of capacity investments since 2019 across resins, filtration, single-use products and media in the U.S., Europe and Asia.
The market is expected to grow 2.4-fold between 2026 and 2036, with bioreactors, bioprocessing containers, cell and gene therapy and CDMOs as the main sources of growth, while sterilizers, incubators and biosafety cabinets grow more slowly as single-use and closed systems replace stainless-steel and open processing.
Biologics account for a growing share of new medicines. The FDA Center for Drug Evaluation and Research approved 46 novel drugs in 2025, including 12 biologics, after 50 in 2024 and 55 in 2023, and the European Medicines Agency authorized 69 new therapies in 2025, up from 64 in 2024. The Antibody Society reported 21 antibody therapeutics granted a first approval in at least one country in 2024, including bispecific antibodies and antibody-drug conjugates, and 30 antibody therapeutics in regulatory review as of December 2024.
Biosimilars add further volume. As of March 2026, 92 biosimilars across 20 molecules had been approved in the U.S., of which 67 had launched, and in October 2025 the FDA issued draft guidance indicating that comparative efficacy studies may no longer be routinely expected, which lowers the cost and time of biosimilar development. As a result, commercial bioproduction is expected to account for 77.6% of the market in 2026.
Biopharmaceutical Plant Capacity Expansions
Major drugmakers announced more than USD 370 billion of U.S. investments in 2025, according to DPR Construction, including a USD 27 billion plan by Eli Lilly for four new plants announced in February 2025 and a USD 55 billion commitment by Johnson & Johnson. The Section 232 proclamation of April 2026 reinforces this trend: about 53% of patented pharmaceutical products distributed in the U.S. are produced abroad, and companies without onshoring agreements face tariffs of up to 100% from September 29, 2026.
CDMOs are also adding capacity. Samsung Biologics reached 784,000 liters of capacity with its fifth plant and plans more than 1.3 million liters once its second Bio Campus is completed. Every new plant requires bioreactors, chromatography systems, filtration and single-use assemblies, followed by recurring consumables once production starts, which explains why Danaher reported mid-teens growth in bioprocessing orders in the second quarter of 2026.
Customer Inventory and Investment Cycles
Customers reduced inventories and delayed capital projects in 2023–2025. Sartorius reported that its bioprocess equipment business declined in 2025 because of industry-wide investment restraint, Avantor reported a 1.8% organic decline in Bioscience Production sales to USD 2,153 million in 2025, and Eppendorf reported an 11.5% decline in its bioprocess business, partly because it discontinued sterilization-in-place products. These cycles make equipment demand more volatile than consumables demand.
Biopharmaceutical Processing Equipment and Consumables Market Opportunities
Shift Toward Bioprocessing 4.0
Connected equipment, in-line process analytical technology, digital twins and automated batch records shorten development and batch release and improve yields. Repligen reported more than 30% growth in analytics in the second quarter of 2026, Sartorius launched the cloud-based Biobrain Operate platform, and Thermo Fisher opened a Bioprocess Design Center in Plainville, Massachusetts, in April 2026 to help customers develop and scale processes.
Intensive Capital Requirements for Biopharmaceutical Production
New biologics plants cost hundreds of millions to billions of dollars and take several years to build and qualify, and capacity decisions are exposed to interest rates, drug pricing policy and trade policy. U.S. most-favored-nation pricing agreements and tariffs create uncertainty for manufacturers deciding where to locate new capacity, and suppliers must fund their own capacity ahead of demand; Sartorius invested EUR 442 million in 2025, 12.5% of sales.
Consolidation Around Filtration, Advanced Therapies and Analytics
Thermo Fisher completed the acquisition of the Solventum purification and filtration business in September 2025, which was expected to generate about USD 750 million of revenue in 2025, Merck KGaA agreed to acquire Bio-Techne in June 2026 to strengthen research, bioprocessing and advanced therapy offerings, and Repligen agreed to acquire BioLife Solutions in July 2026.
Biopharmaceutical Processing Equipment and Consumables Market Segment Analysis
Market dynamics
5 factors across 1 forceRising Adoption of Single-use Bioprocessing Equipment
Single-use systems eliminate cleaning and sterilization, reduce the use of water for injection and steam, and shorten changeovers between products, which suits multi-product and CDMO facilities. The revised EU GMP Annex 1, applicable since August 2023, requires a contamination control strategy for sterile manufacturing that favors closed, pre-sterilized systems. Sartorius reported that consumables such as filters and single-use bags drove its 2025 growth, and single-use bioreactors are projected to grow at 12.8%, compared with 7.2% for reusable systems.
Biopharmaceutical Processing Equipment and Consumables Market Restraints
Complexities in the Development & Manufacturing of Biopharmaceuticals
Biologics are produced in living cells, and small process changes can alter product quality. Changes to equipment, consumables or suppliers therefore require comparability studies and regulatory approval, which makes customers reluctant to adopt new technologies for approved products. Product-specific demand can also be volatile: Danaher reported in July 2026 that customer-requested delays of chromatography resin shipments would shift a little more than USD 100 million of bioprocessing revenue out of 2026, and Bio-Rad reported a 13% currency-neutral decline in process chromatography in the first quarter of 2026 against a tough comparison.
Asia-Pacific is projected to register the highest CAGR of 10.3% during the forecast period,
led by India at 12.4%, South Korea at 11.0% and China at 10.8%. Repligen reported about 40% growth in Asia-Pacific in the second quarter of 2026 and more than 60% growth in China in the first half of 2026, Thermo Fisher reported that China returned to growth in the same quarter, and Sartorius is building a new site in Songdo, South Korea, to serve the region.
Biopharmaceutical Processing Equipment and Consumables Market Challenges
Use of Disposable Processing Equipment for Commercial Production
Single-use technologies, first adopted for clinical manufacturing, are moving into commercial production through scale-out with multiple 2,000-liter bioreactors. Bioprocessing containers are projected to grow at 10.1%, faster than the market, while sterilizers are projected to grow at 6.8%, the lowest rate among product types.
Rising Focus on Continuous Bioprocessing and Process Intensification
Perfusion upstream processes, high-density cell banks and continuous or multi-column chromatography increase productivity and reduce facility size. Repligen reported an improvement in ATF perfusion order trends in 2026, and Cytiva has doubled chromatography resin capacity in Uppsala, Sweden, to meet demand for high-capacity resins.
Table of contents
11 chapters · 206 sections · 280 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product Type | Filtration Systems | Bioreactors |
| By Application | Monoclonal Antibody Production | Cell and Gene Therapy |
| By End User | Pharmaceutical & Biopharmaceutical Companies | CDMOs |
| Other segments | Danaher, Thermo Fisher Scientific, Merck KGaA and Sartorius | — |
By Product Type
- The global Biopharmaceutical Processing Equipment and Consumables Market is segmented into Filtration Systems, Chromatography Equipment and Consumables, Bioreactors, Cell Culture Products, Bioprocessing Containers, Sterilizers, Mixers/Mixing Systems, Incubators, Centrifuges, Shakers, Biosafety Cabinets, Other Consumables and Accessories, and Support Services.
- The Filtration Systems segment is expected to account for the largest share of 21.1% of the market.
- The large share of this segment is attributed to the use of filtration at almost every step of production, from sterile filtration of media and buffers to clarification, virus filtration, tangential flow filtration and final sterile filtration, and to the single-use nature of filters.
- However, the Bioreactors segment is projected to register the highest CAGR of 11.0% during the forecast period, driven by new commercial capacity and the adoption of single-use bioreactors.
By Application
- The market is segmented into Commercial Bioproduction (Monoclonal Antibody Production, Therapeutic Protein Production, Vaccine Production, and Cell and Gene Therapy) and Research Bioproduction.
- The Commercial Bioproduction segment is expected to account for the larger share of 77.6% of the market, because commercial batches consume far more media, resins, filters and single-use products than research.
- Monoclonal Antibody Production is the largest commercial application, while Cell and Gene Therapy is projected to register the highest CAGR of 14.3% and Vaccine Production the lowest, as demand normalizes after the COVID-19 peak.
By End User
- The market is segmented into Pharmaceutical & Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), and Academic & Research Institutes.
- The Pharmaceutical & Biopharmaceutical Companies segment is expected to account for the largest share of 58.3% of the market, reflecting in-house production of most commercial biologics and large new U.S. investments by drugmakers.
- However, the CDMOs segment is projected to register the highest CAGR of 11.1% during the forecast period, driven by outsourcing by emerging biotech companies and capacity additions in South Korea, China, India and Switzerland, while Academic & Research Institutes grow slowest, at 7.8%, because of research funding pressure.
Other segments
- Biopharmaceutical Processing Equipment and Consumables Market Competitive Landscape
- The global Biopharmaceutical Processing Equipment and Consumables Market combines diversified life science companies, specialized bioprocessing suppliers and laboratory equipment manufacturers.
- Market participants compete primarily on product performance and validation data, breadth of portfolio across upstream and downstream processing, supply security and in-region manufacturing, regulatory support and price.
- Between January 2024 and September 2026, the profiled companies reported 28 month-dated strategic developments, led by acquisitions (17), expansions (4) and product launches (3).
- Danaher, Thermo Fisher Scientific, Merck KGaA and Sartorius lead the market, together accounting for an estimated 45%–50% of sales.
- The key players profiled in the report include Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Sartorius AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), Avantor, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eppendorf SE (Germany), Solaris Biotechnology Srl (Italy), and Repligen Corporation (U.S.).
- Avantor replaces 3M Company from the previous edition, because the former 3M health care business, Solventum, sold its purification and filtration business to Thermo Fisher in 2025.
Geographic analysis
Europe
Largest shareIn 2026, Europe is expected to account for the largest share of 33.6% of the global Biopharmaceutical Processing Equipment and Consumables Market. The large share of Europe is attributed to its concentration of biologics plants and CDMOs in Germany, Switzerland, Ireland, Denmark and Belgium and the presence of leading suppliers, such as Sartorius, Merck KGaA and Eppendorf. Sartorius reported first-quarter 2026 sales of EUR 392 million in EMEA, up 8.0% in constant currencies. Germany is expected to account for the largest share of 25.0% of the regional market in 2026, while Denmark (9.4%) and Ireland (9.0%) are projected to grow fastest, supported by protein therapeutic and antibody capacity additions.
North America
North America is expected to account for the second-largest share of 31.0% of the market in 2026 and to grow at a CAGR of 9.3%, faster than Europe. The U.S. is expected to account for 94.8% of the regional market, supported by more than USD 370 billion of drugmaker investment pledges, Section 232 tariffs on patented pharmaceutical imports from September 2026, and supplier investments such as the second Cytiva resin plant in Michigan and the Thermo Fisher Bioprocess Design Center opened in April 2026.
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR of 10.3% during the forecast period. The growth of this region is driven by CDMO expansion in South Korea, where Samsung Biologics reached 784,000 liters of capacity and 18 biosimilars were approved in 2024, the recovery of domestic biologics and CDMO demand in China, and vaccine and biosimilar production in India. China is expected to account for the largest share of 36.4% of the regional market in 2026, while India is projected to register the highest CAGR of any country, at 12.4%.
Latin America
Latin America is expected to account for a share of 3.3% of the market in 2026. The market is driven by vaccine producers such as Instituto Butantan and Fiocruz in Brazil and growing biosimilar production in Brazil and Mexico, while limited capital budgets favor stainless-steel and lower-cost equipment.
Middle East & Africa
The Middle East & Africa is expected to account for a share of 1.9% of the market in 2026 and to grow at a CAGR of 9.8%, driven by local vaccine and biologics manufacturing initiatives in Saudi Arabia, the United Arab Emirates, Egypt and South Africa.
Competitive landscape
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Sartorius AG
- Danaher Corporation
- Merck KGaA
- Avantor, Inc.
- Bio-Rad Laboratories, Inc.
- Eppendorf SE
- Solaris Biotechnology Srl
- Repligen Corporation
Expert perspectives
The Biopharmaceutical Processing Equipment and Consumables Market has moved past the post-pandemic destocking cycle and is entering a new investment phase. Consumables recovered first in 2025, and equipment orders began to follow in 2026 as drugmakers and CDMOs committed to new plants. Because every new commercial biologic locks in consumables demand for its lifetime, current capacity announcements support recurring revenue well into the 2030s.
Three structural changes are expected to shape competitive positions through 2036. First, trade policy is regionalizing production: U.S. tariffs on patented pharmaceuticals favor domestic plants, and customers expect suppliers to manufacture critical consumables in the region they serve. Second, modalities are diversifying beyond monoclonal antibodies into antibody-drug conjugates, bispecifics, cell and gene therapies and biosimilars, which increases demand for specialized media, single-use systems and purification. Third, consolidation is creating integrated suppliers, as shown by the Solventum filtration, Bio-Techne and BioLife Solutions transactions.
For companies planning entry or expansion, the most attractive positions are likely to be found in single-use bioreactors and assemblies, high-capacity chromatography resins, filtration for new commercial plants, cell and gene therapy consumables, process analytics and supply of CDMOs in Asia-Pacific. For established suppliers, the principal risks are customer investment cycles, order timing volatility and price pressure from biosimilar producers and regional competitors.
Frequently asked questions
The global Biopharmaceutical Processing Equipment and Consumables Market is estimated at USD 44.8 billion in 2026.
Cite this report
Meticulous Research. (2026). Biopharmaceutical Processing Equipment and Consumables Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-58). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/biopharmaceutical-processing-equipment-and-consumables-market-4200